Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review
ABSTRACT Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH). We conducted a systematic review to compare the efficacy and safety of burosumab versus conventional therapy (phosphorus and cal...
| Prif Awduron: | , , , , , , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Brazilian Society of Endocrinology and Metabolism
2024-06-01
|
| Cyfres: | Archives of Endocrinology and Metabolism |
| Pynciau: | |
| Mynediad Ar-lein: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972024000100707&tlng=en |